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ABSTRACT
Background: Synthesis of thyroid hormones and regulation of their metabolism
involve free radicals that may affect redox balance in the body. Thyroid disorders
causing variations in the levels of thyroid hormones may alter cellular oxidative
stress. The aim of this study was to measure the antioxidant activities and
biomarkers of oxidative stress in serum and red blood cells (RBC) of patients with
benign and malignant thyroid disorders and to investigate if changes in the
antioxidant activities in these patients were linked to alterations in genes encoding
the antioxidant enzymes.
Methods: Forty-one patients with thyroid disorders from University of Malaya
Medical Centre were recruited. They were categorised into four groups:
multinodular goitre (MNG) (n = 18), follicular thyroid adenoma (FTA) (n = 7),
papillary thyroid cancer (PTC) (n = 10), and follicular thyroid cancer (FTC) (n = 6).
Serum and RBC of patients were analysed for antioxidant activities, antioxidant
enzymes, and biomarkers of oxidative stress. Alterations in genes encoding the
antioxidant enzymes were analysed using whole exome sequencing and PCR–DNA
sequencing.
Results: Patients with thyroid disorders had significantly higher serum superoxide
dismutase (SOD) and catalase (CAT) activities compared to control, but had lower
activities in RBC. There were no significant changes in serum glutathione peroxidase
(GPx) activity. Meanwhile, GPx activity in RBC was reduced in PTC and FTC,
compared to control and the respective benign groups. Antioxidant activities in
serum were decreased in the thyroid disorder groups when compared to the control
group. The levels of malondialdehyde (MDA) were elevated in the serum of FTA
group when compared to controls, while in the RBC, only the MNG and PTC groups
showed higher MDA equivalents than control. Serum reactive oxygen species (ROS)
levels in PTC group of both serum and RBC were significantly higher than
control group. Whole exome sequencing has resulted in identification of 49 single
nucleotide polymorphisms (SNPs) in MNG and PTC patients and their genotypic
and allelic frequencies were calculated. Analyses of the relationship between
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serum enzyme activities and the total SNPs identified in both groups revealed
no correlation.
Discussion: Different forms of thyroid disorders influence the levels of antioxidant
status in the serum and RBC of these patients, implying varying capability of
preventing oxidative stress. A more comprehensive study with a larger target
population should be done in order to further evaluate the relationships between
antioxidant enzymes gene polymorphisms and thyroid disorders, as well as
strengthening the minor evidences provided in literatures.
Subjects Biochemistry, Molecular Biology, Oncology, Medical Genetics, Metabolic Sciences
Keywords Thyroid disorders, Antioxidants, Antioxidant enzymes, Whole exome sequencing,
Single nucleotide polymorphisms, Oxidative stress
INTRODUCTION
Thyroid hormones play important roles in the body including regulating metabolic
rate and oxidative metabolism as well as stimulating growth and protein synthesis.
Thyroid gland dysfunction is known to alter lipid profiles, potentially causing
conditions such as hypertension, insulin resistance and oxidative stress. During the
production of thyroid hormones, reactive oxygen species (ROS) are generated as part
of the process. However, under normal redox balance, the ROS are removed by
antioxidant systems in the body, hence limiting oxidative damage. On the other
hand, certain conditions such as inflammation of the thyroid gland as well as
tumour cell proliferation could alter the balance between ROS and antioxidant levels
(Cetin et al., 2015) in favour of the former, subsequently leading to oxidative
damage (Erdamar et al., 2010). In particular, the utilisation of H2O2 for thyroid
hormones synthesis causes the thyroid to be easily exposed to oxidative stress in
situation where there is disorder in thyroid hormones production (Karbownik-
Lewinska & Kokoszko-Bilska, 2012).
Several studies have shown the link between oxidative stress and cancer, including
thyroid cancer (Florian et al., 2010; Noda & Wakasugi, 2001;Wang et al., 2011). Although
some information is known about the antioxidant status of patients with thyroid
disorders (Erdamar et al., 2010; Senthil & Manoharan, 2004; Wang et al., 2011),
comparisons between the benign and malignant groups have rarely been performed,
especially on two types of benign thyroid disorders which are multinodular goitre (MNG)
and follicular thyroid adenoma (FTA). Hence, this study focuses on MNG and FTA as
the benign groups, while two of the most common thyroid cancers, papillary thyroid
cancer (PTC) and follicular thyroid cancer (FTC) as the malignant groups. Such
comparisons can provide data on the potential associations between oxidative stress
and development of malignant form from the benign cases.
As the metabolic effects of thyroid hormones are linked to oxidative stress, genetic
variations in antioxidant enzymes may also have an impact on the endogenous
antioxidant defence system (Da Costa, Badawi & El-Sohemy, 2012; Maier et al., 2007).
There is a lack of studies investigating the genetic variations of antioxidant enzymes in
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relation to thyroid disorder-associated oxidative stress, particularly through single
nucleotide polymorphism (SNP) analyses.
Therefore, the aim of this study was to analyse the antioxidant status in patients
with thyroid disorders by measuring antioxidant activities and parameters of oxidative
stress including antioxidant enzyme activities, lipid peroxidation and levels of ROS.
In addition, nucleotide alterations in genes encoding the antioxidant enzymes, superoxide
dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT), were screened in
order to assess the underlying genetic cause that may be linked to thyroid disorders.
For the screening of gene alterations, whole exome sequencing (WES) analysis were
performed in both MNG (n = 9) and PTC (n = 9) groups as they are the most common
form of thyroid disorders. To minimise cost, gene alterations detected in the MNG
and PTC patients were reanalysed in patients with FTC (n = 5); a less common form
of thyroid cancer, by PCR–DNA sequencing analysis.
MATERIALS AND METHODS
Subjects
A total of 41 patients with thyroid gland disorders from University of Malaya Medical
Centre, Kuala Lumpur were involved in this study. Consents were obtained from all the
patients before proceeding with the collection of samples. Ethical clearance for this study
was obtained from the UMMC medical ethics committee (reference number: 925.8).
The patients were categorised into four groups according to their diagnosis of thyroid
gland disorders; MNG, FTA, PTC, and FTC. Their blood samples were taken prior to
surgery, for antioxidant analyses and thyroid function tests. In addition, a total of 14
healthy subjects served as control group. Blood samples of the patients and control group
were sent to Clinical Diagnostic Laboratory (CDL) of UMMC for the analyses of TFT
using ADVIA Centaur CP Immunoassay System (TSH normal reference: 0.55–4.78 mU/L;
fT4 normal reference: 11.5–22.7 pmol/L) (Table 1).
Meanwhile tissue samples of thyroid glands taken from patients with thyroid
disorders were used for analyses of genes encoding the antioxidant enzymes. For the WES
analysis, selected patients from theMNG (n = 9) and PTC (n = 9) groups were included. For
comparison, genes alterations detected in the MNG and PTC patients were also analysed in
the FTC patients, using PCR–DNA sequencing. Tissue samples were extracted from the
nodule and their clinical diagnoses were confirmed by histopathological examination via
H&E stain. The tissue samples were kept fresh-frozen prior to DNA extraction.
Blood samples
Blood (3 mL) was drawn by venepuncture from the subjects. Serum was collected into BD
Vacutainer SST tube and was centrifuged at 2,236g for 15 min at 4 C. Whole blood
was collected into BD Vacutainer K2EDTA tube and centrifuged at 2,236g for 15 min at
4 C to separate plasma and red blood cells (RBC). Plasma was isolated and the RBC
was washed with phosphate buffered saline (PBS) three times, followed by centrifugation
at 1,000g for 5 min at 4 C. Double distilled water was added into the tube, and the RBC
was allowed to lyse for 2 h at 4 C. After the incubation, RBC was centrifuged at 2,000g for
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15 min at 4 C. The supernatant, containing lysed RBC, and the serum samples were
stored at -80 C until further analysis.
Superoxide dismutase
Superoxide dismutase enzyme activity was measured using commercially available SOD
Assay Kit (Cayman, Ann Arbor, Michigan, USA) according to the manufacturer’s protocol.
Serum and RBC samples were diluted to 1:5 and 1:100 with sample buffer, respectively. The
measurement was based on the activity of SOD in the sample to cause dismutation of
the superoxide radicals generated by xanthine oxidase and hypoxanthine. The absorbance
was read at 450 nm. One unit of SOD is defined as the amount of enzyme needed to exhibit
50% dismutation of the superoxide radicals. The analyses were performed in triplicate.
Catalase
Catalase enzyme activity was measured using commercially available CAT Assay Kit
(Cayman, USA) according to the manufacturer’s protocol. The assay utilised the
peroxidatic function of the enzyme. Formaldehyde served as the standard, and samples
were diluted with sample buffer in a ratio of 1:5 for serum, and 1:1,000 for RBC prior
to the assay. The reactions were initiated with the addition of H2O2. The assay is based
on the reactions of CAT with methanol in the presence of H2O2. The absorbance was
read at 550 nm using a plate reader. CAT activity was expressed as unit per millilitre
whereby one unit is defined as the amount of enzyme that will cause the formation of
1.0 nmol of formaldehyde per minute at 25 C. The assays were done in triplicate.
Glutathione peroxidase
Glutathione peroxidase enzyme activity was measured using commercially available
GPx Assay Kit (Cayman Chemical, Ann Arbor, MI, USA), according to the manufacturer’s
protocol. Serum and RBC samples were diluted into 1:10 ratio with sample buffer.
GPx activity was measured indirectly by a coupled reaction with glutathione reductase,
and the reactions were initiated by the addition of cumene hydroperoxide. The
absorbance was read every minute at 340 nm for 5 min using a plate reader to obtain five
time points. GPx activity was expressed as unit per millilitre whereby one unit is defined as
the amount of enzyme that will cause the oxidation of 1.0 nmol of NADPH to NADP+
per minute at 25 C. All analyses were performed in triplicate.
Table 1 Demographic and clinical characteristics of patients with their thyroid function test (TFT)
results.
Control (n = 14) MNG (n = 18) FTA (n = 7) PTC (n = 10) FTC (n = 6)
Age (years) 32.5 (29–66) 53.5 (35–71) 34 (14–72) 49.5 (22–76) 57.5 (35–80)
Gender F: 11 M: 3 F: 16 M: 2 F: 6 M: 1 F: 5 M: 5 F: 6 M: 0
TSH (mU/L) 1.24 (0.43–3.1) 1.02 (0.17–5.35) 1.98 (0.88–2.74) 1.73 (0.41–4.63) 1.13 (0.01–2.51)
fT4 (pmol/L) 16.3 (13.6–21.5) 16.1 (12.0–20.2) 17.9 (14.2–19.4) 16.7 (13.7–19.2) 16.05 (12.4–44.5)
Notes:
Data are presented as median. Patient groups: MNG, multinodular goitre; FTA, follicular thyroid adenoma; PTC,
papillary thyroid cancer; FTC, follicular thyroid cancer. Gender: Female (F), Male (M). TSH, thyroid-stimulating
hormone (normal reference: 0.55–4.78 mU/L); fT4, free thyroxine (normal reference: 11.5–22.7 pmol/L).
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ABTS radical scavenging activity
The 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) radical scavenging
activity in the blood samples was measured based on the method ofMagalha˜es et al. (2008)
with slight modification. ABTS (7 mM) and potassium persulphate (2.45 mM) were mixed
together to generate ABTS+ radical cation by incubating the solution in the dark at
room temperature for 16 h. The solution was then diluted with methanol to obtain an
absorbance of 0.70 ± 0.02 at 415 nm. Four microliters of samples (serum or RBC) were
added to 400 mL of ABTS reagent and the mixture was incubated in the dark for 10 min.
After incubation, the sample was centrifuged at 1,643g for 1 min, and the absorbance of the
supernatant was read at 415 nm. Trolox was used as standard and was similarly analysed as
above. Trolox standard curve was plotted with a concentration range of 0, 0.5, 1, 1.5, and
2 mM. The final results were expressed as Trolox equivalent antioxidant capacity (TEAC).
ROS scavenging assay
Dichlorofluorescein diacetate (DCF-DA) was used as the fluorescence-based probe for
the detection of ROS in the blood samples. In the assay, 5 mL of sample and 100 mL of
DCF-DA reagent (20 mM) were added into a black 96-well plate and was incubated
for 30 min at room temperature. Fluorescence reading was taken with the excitation
and emission wavelengths set at 485 and 530 nm, respectively (Bioplex 200 Systems)
(Bio-Rad, Hercules, CA, USA). All reactions were done in triplicate. Results were
expressed as relative fluorescence unit.
Lipid peroxidation
Thiobarbituric acid reactive substances (TBARS) assay was used in estimating lipid
peroxidation in the blood samples. Malondialdehyde (MDA) as the by-product of lipid
peroxidation, reacted with thiobarbituric acid (TBA) to form TBARS. TBARS reagent
was prepared by mixing 0.3 g of TBA, 12 g of trichloroacetic acid (TCA) and 1.04 mL of
70% perchloric acid (HClO4) in 80 mL of double-distilled water. Sample (50mL) was mixed
with 250 mL of TBARS reagent and boiled at 90 C for 20 min. After cooling on ice, the
mixture was centrifuged at 309g for 10 min at 25 C. Absorbance of the supernatant was
read at 532 nm (Bio-Rad Model 680 Microplate Reader, Hercules, CA, USA). A standard
curve was constructed using 1,1,3,3-tetraethoxypropane (TEP) (0–100 ng/mL). Protein
content of the sample was measured using Bradford protein assay, with bovine serum
albumin (BSA) as the standard. The levels of lipid peroxidation were expressed as nanomole
MDA equivalents per milligram of protein. All analyses were performed in triplicate.
Molecular analysis
DNA extraction and whole exome sequencing
DNA samples of the patients; MNG (n = 9) and PTC (n = 9), were sent to BGI Tech
Solutions, Shenzhen, China for WES analysis. The protocols were based on the Agilent
SureSelect XT Target Enrichment System for Illumina Paired-End Sequencing which
involved the following steps; library preparation, hybridisation and capture, and
sequencing. The raw image files obtained from the sequencing were processed using
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the Illumina Software 1.7 via base-calling, and the raw data was saved in the FASTQ
format. The quality control (QC) step was performed using FastQC (www.bioinformatics.
babraham.ac.uk). Data filtering was applied to the FASTQ data and the sequencing reads
were aligned to the Reference Genome of human genome build37 (hg19) using BWA
software (http://bio-bwa.sourceforge.net). The SOAPsnp software was used for SNP
calling (http://soap.genomics.org.cn) and following identification of SNPs, an in-house
AnnoDB software (AnnotationDB) was used for RefGene annotation.
SNP genotyping of FTC patients
TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA) were used to
amplify specific SNP alleles in purified DNA samples of FTC (n = 5) patients using
real-time polymerase chain reaction (qRT-PCR). The list of genes with their respective
SNP primers used for the qRT-PCR are listed in Table 2. qRT-PCR amplification was
performed in 0.2 mL MicroAmp Optical 8-tube strips in a final volume of 10 mL that
consisted of 5 mL of 2 TaqMan Genotyping Master Mix, 0.5 mL of TaqMan DME
Genotyping Assay Mix, and genomic DNA diluted in distilled water (10 ng). qRT-PCR
was performed using the following PCR parameters; 10 min of initiation steps at 95 C,
followed by 50 cycles of denaturation at 92 C for 15 s, and annealing steps for 90 s.
Statistical analyses
All data for antioxidant analyses were expressed as mean ± SEM, unless otherwise stated.
The Statistical Package for Social Sciences (SPSS) version 24.0 (IBM, New York, NY, USA)
was used to perform the following statistical analyses. One-way analysis of variance
(ANOVA) was used to compare the mean differences of serum and RBC antioxidant
analyses between the groups of subjects for all normally distributed dataset whilst the non-
parametric Kruskal–Wallis test was used, if otherwise. The Tukey post-hoc test was used
for multiple comparisons of specific sample pairs when equal variances were assumed
whilst Dunnett’s T3 post-hoc test was used when unequal variances were assumed.
Levene’s test of homogeneity of variances was used to verify the assumption. Spearman’s
correlation coefficient test was used to compare the association between SNPs and
antioxidant enzyme activities among MNG and PTC groups of subjects.
Table 2 List of genes and SNP primers of TaqMan SNP Genotyping Assays.
Gene dbSNP SNP Context sequences[VIC/FAM]1 TaqMan assay ID
SOD2 rs752779 ACTTGTTCCTATAGCATTTAAAAAG[A/G]TCTCCCTGTACCTGTGCTGCATATT C__630044_10
SOD3 rs2536512 CATGCAGCGGCGGGACGACGACGGC[A/G]CGCTCCACGCCGCCTGCCAGGTGCA C__2668728_10
GPX3 rs3763011 TTTAAGCACTTAATATTAAGTACCC[A/G]AAAAGCACTTATTAAGTGCTTTCAT C__27513029_10
GPX3 rs8177447 CCTCAAGCAAGGTTGACACTCCTCT[C/T]ATCCCTGCTCTAGAACTCCTGTCCT C__30052985_10
GPX7 rs1970951 AGCGAGACCTGGGCCCCCACCACTT[C/T]AACGTGCTCGCCTTCCCCTGCAACC C__11730536_10
GPX8 rs381852 GAGGGTCAAGTTGTGAAGTTCTGGA[A/G]GCCAGAGGAGCCCATTGAAGTCATC C__9528830_10
CAT rs769217 CTCGAGTGGCCAACTACCAGCGTGA[C/T]GGCCCGATGTGCATGCAGGACAATC C__3102907_10
CAT rs769218 ATTGCAAAGCTATGTACCCGTGACA[A/G]TGTAAATGAAAGGTTTGATTGTGCT C__3102900_10
Note:
1 Shows a reporter dye for the specific alleles underlined and highlighted in blue. Each assay mix concentration is 40 in 188 mL per tube. The amplicon size is NA.
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Hardy–Weinberg (HW) exact test was used to test the genetic equilibrium of the SNPs
using Genepop (version 4.2) population genetics software package (Raymond & Rousset,
1995; Rousset, 2008). The distribution of alleles and genotypes of SNPs between MNG,
PTC, and FTC were analysed using Fisher’s exact test. p-values less than 0.05 were
considered significant.
RESULTS
Table 1 shows the demographic and clinical characteristics of patients, together with their
thyroid function tests. The patients’ age ranged from 14 to 80 years old while the controls
ranged from 29 to 66 years old. Only two patients were diagnosed with thyroiditis,
implying that thyroiditis is not common among the recruited patients. There was no
significant difference between the TSH concentration and fT4 values between the control
group and the thyroid disorder groups (p > 0.05).
Antioxidant response and oxidative stress in serum
Figures 1A–1C shows the antioxidant enzyme activities in serum of control and patients.
Patients from the MNG and PTC groups had significantly higher levels of SOD activities
(more than fourfold) compared to control (Fig. 1A). Out of the four thyroid disorder
groups, only MNG showed higher CAT activities than control (Fig. 1B). Meanwhile,
there were no significant differences in GPx activities between control subjects and the
thyroid disorder groups (Fig. 1C).
Analysis of ABTS radical scavenging activity shows the thyroid disorder groups to have
significantly lower antioxidant activities than the control group (p < 0.05) (Fig. 1D).
Amongst the four diseased groups, PTC showed the lowest ABTS radical scavenging
activity which was significantly lower than its benign form, MNG. Lipid peroxidation was
estimated by measuring levels of MDA, a by-product of lipid peroxidation. Levels of MDA
equivalents were found to be significantly increased in the FTA group, compared to
control while there was not significant difference in the remaining groups (Fig. 1E).
Another parameter for oxidative stress that was measured was levels of ROS (Fig. 1F).
ROS level was significantly higher in the PTC group, compared to control while there were
no changes in the remaining groups.
Antioxidant response and oxidative stress in RBC
Figures 2A–2C shows the antioxidant enzyme activities in RBC of control and patients.
Patients with MNG and FTC had significantly lower SOD activities than control (Fig. 2A).
Amongst the four thyroid disorder groups, the FTA group showed lower CAT activities
than control (Fig. 2B). GPx activities of the malignant groups (PTC and FTC) were
significantly lower than the benign (MNG and FTA) and control groups (p < 0.05). On
the contrary, there were no significant changes in the MNG and FTA groups when
compared to control (p > 0.05) (Fig. 2C).
Analysis of ABTS radical scavenging activities indicated no significant changes among
the thyroid disorder groups with that of control (Fig. 2D). However, levels of MDA
equivalents in MNG and PTC groups were significantly higher than the control group
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(Fig. 2E) while only the PTC group showed significantly higher level of ROS compared to
control (Fig. 2F).
Single nucleotide polymorphisms in patients
Whole exome sequencing analysis of MNG (n = 9) and PTC (n = 9) revealed 11 SNPs
in SOD gene, 28 SNPs in GPX gene, and 10 SNPs in CAT gene (Table 3). Out of the total
49 SNPs identified from the sequencing, eight SNPs were observed to be commonly
present in both groups of thyroid disorders and in five of the FTC patients (Table 4).
Figure 1 Antioxidant analysis in serum samples of thyroid patients. 1a: SOD activity; 1b: CAT
activity; 1c: GPx activity; 1d: ABTS radical scavenging activity, expressed as Trolox Equivalent Anti-
oxidant Activity (TEAC); 1e: lipid peroxidation assay measured as MDA concentration; 1f: ROS analysis.
# Indicates significant difference (p < 0.001) between the diseased groups of benign and malignant
thyroid disorders (MNG vs PTC, FTA vs FTC).  indicates significant difference (p < 0.05 and > 0.01)
between control and the diseased groups.  indicates significant difference (p < 0.01 and > 0.001) between
control and the diseased groups.  indicates significant difference (p < 0.001) between control and the
diseased groups.
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Thus, Venn diagrams (Fig. 3) were constructed to show the distribution of these SNPs in
all the three groups; MNG, PTC, and FTC. These diagrams provide information on
patients sharing similar polymorphisms among the three types of thyroid disorders
groups. The most common SNP for SOD gene is rs752779, detected in all MNG patients
(n = 9), eight PTC patients and in all FTC patients (n = 5). Meanwhile rs2536512 was
detected in six PTC patients and only in three of MNG and FTC patients. For the GPX
gene, four SNPs are found to be common; rs1970951, rs381852, rs3763011, and
Figure 2 Antioxidant analysis in red blood cells samples of thyroid patients. (A) SOD activity; (B)
CAT activity; (C) GPx activity; (D) ABTS radical scavenging activity, expressed as Trolox Equivalent
Antioxidant Activity (TEAC); (E) lipid peroxidation assay measured as MDA concentration; (F) ROS
analysis. # Indicates significant difference (p < 0.001) between the diseased groups of benign and
malignant thyroid disorders (MNG vs PTC, FTA vs FTC).  indicates significant difference (p < 0.05
and > 0.01) between control and the diseased groups.  indicates significant difference (p < 0.01 and
> 0.001) between control and the diseased groups.  indicates significant difference (p < 0.001) between
control and the diseased groups.
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Table 3 Characteristics and localisations of SNPs in SOD2, SOD3, GPX1, GPX2, GPX3, GPX4, GPX6,
GPX7, GPX8, and CAT genes in patients with MNG and PTC.
Gene dbSNP Location Types of variants Base; amino acid change
SOD2 rs4880 Exon 2 Missense A/G; V16A
Ch6 rs752779 Intergenic – G/A;–
q25.3 rs2758332 Intron 3 – C/A;–
rs2855116 Intron 3 – A/C;–
rs2070994 Intron 3 – A/T;–
rs2842960 Intron 2 – C/T;–
SOD3 rs8192291 Exon 2 Synonymous C/T; L71L
Ch4 rs1799895 Exon 2 Missense C/G; R231G
p15.2 rs2695232 UTR3′ – C/T;–
rs2855262 UTR3′ – T/C;–
rs2536512 Exon 2 Missense G/A; A58T
GPX1 rs368623389 Exon 1 Missense T/C; E89G
Ch3
p21.3
GPX2 rs17881414 Intron 1 – T/C;–
Ch14
q23.3
GPX3 rs11548 UTR3′ – C/T;–
Ch5 rs2070593 UTR3′ – G/A;–
q33.1 rs2277940 UTR3′ – T/C;–
rs8177413 Exon 1 Synonymous G/C; L13L
rs2230303 UTR3′ – T/G;–
rs8177448 UTR3′ – G/A;–
rs8177412 UTR5′ – T/C;–
rs3763012 Intron 1 – G/A;–
rs3763011 Intron 1 – G/A;–
rs869975 Intron 2 – G/A;–
rs8177447 Intron 4 – T/A;–
rs870407 Intron 1 – A/G;–
rs870406 Intron 1 – G/A;–
rs869976 Intron 2 – A/G;–
GPX4 rs713041 UTR3′ – T/C;–
Ch19 rs4807542 Exon 1 Synonymous G/A; P12P
p13.3 rs569667691 Exon 7 Synonymous G/A; L193L
rs8178977 Intron 6 – G/C;–
GPX6 rs372898956 Exon 4 Synonymous C/T; V122V
Ch6 rs974334 Intron 2 – C/G;–
p22.1
GPX7 rs1970951 Exon 2 Synonymous T/C; F79F
Ch1 rs11810754 UTR5′ – T/G;–
p32 rs1970950 Intron 2 – A/G;–
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rs8177447. Eight MNG and all PTC patients appeared to have rs1970951 and rs381852,
whereas the former and the latter SNPs was detected in four and three of the FTC patients,
respectively. Four FTC and seven patients from each of the MNG and PTC groups have
rs3763011. The same FTC and MNG patients as well as all PTC patients have rs8177447.
The CAT SNPs; rs769217 and rs769218 were shared by the same patients of MNG (n = 4)
and PTC (n = 7). Meanwhile all FTC patients (n = 5) have rs769217, and only four FTC
patients have rs769218 (Fig. 3).
Analysis on genotypic and allelic frequencies
Genotypic and allelic frequencies in MNG, PTC, and FTC patients of the eight SNPs
are summarised in Table 4. The HW Exact test showed that the genotype and allele
frequencies in all SNPs conformed to HW equilibrium (p > 0.05). The allelic frequency
distribution of the eight SNPs (HW—p > 0.05) in our studied populations was then
compared with the healthy subjects of South Asian (SAS) and East Asian (EAS) countries,
taken from the database of 1000 Genomes Project Phase 3 allele frequencies (Yates
et al., 2016). The populations were categorised as SAS, EAS, MNG, PTC, and FTC, and the
data are presented in Fig. 4 according to their allele frequencies.
Significant differences were detected in the genotype frequencies for two SNPs;
rs752779 (p = 0.03) and rs1970951 (p = 0.05) among the MNG, PTC, and FTC groups
(Table 4). For the rs752779, the majority of patients with PTC have GA genotype (78%)
whilst patients with FTC have GG genotype (80%). Meanwhile, for the rs1970951, the
majority of patients with MNG and PTC have TT genotype (67% and 78%, respectively)
whilst patients with FTC have TC genotype (80%). A significant difference in frequency
was also observed for the T/C allele for the rs1970951 SNP but not for the G/A allele in
Table 3 (continued).
Gene dbSNP Location Types of variants Base; amino acid change
GPX8 rs381852 Exon 3 Missense A/G; K182R
Ch5 rs10059517 UTR3′ – T/C;–
q11.2 rs2270910 Intron 1 – C/G;–
CAT rs769217 Exon 9 Synonymous C/T; D389D
Ch11 rs704724 Exon 10 Synonymous C/T; L419L
p13 rs1049982 UTR5′ – T/C;–
rs7943316 UTR5′ – A/T;–
rs10836235 Intron 1 – C/T;–
rs769218 Intron 1 – G/A;–
rs17881488 Intron 11 – C/A,–
rs12270780 Intron 1 – G/A;–
rs2073058 Intron 7 – A/G;–
rs16925614 Intron 11 – C/T;–
Note:
V16A, Valine16Alanine; L71L, Leucine71Leucine; R231G, Arginine231Glycine; A58T, Alanine58Threonine; E89G,
Glutamic acid89Glycine; L13L, Leucine13Leucine; P12P, Proline12Proline; L193L, Leucine193Leucine; V122V,
Valine122Valine; F79F, Phenylalanine79Phenylalanine; K182R, Lysine182Arginine; D389D, Aspartic acid389Aspartic
acid; L419L, Leucine419Leucine.
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the rs752779 SNP. All of the other SNPs did not show significant differences in both
genotypic and allelic frequencies.
Relationship between serum enzyme activities and total SNPs
identified
The overall results of the total 49 SNPs for the antioxidant enzymes were compared
with the respective antioxidant enzyme activities to ascertain if any correlation exists
between these two factors, in MNG and PTC patients. The analysis did not demonstrate
any correlation between total SNPs and the corresponding antioxidant enzyme activities
in the two groups (Fig. 5).
DISCUSSION
Thyroid disorders are more common among females with an estimated incidence
of 2%, whereas it is only 0.2% in males. In fact, being female constitute one of the
Table 4 Genotype and allele frequencies of the eight SNPs in MNG, PTC, and FTC patients.
SNPs Genotype Number of patients (%)1 p-value Allele Total haplotypes (%)2 p-value
MNG (n = 9) PTC (n = 9) FTC (n = 5) MNG PTC FTC
rs752779 GG 4 (44) 1 (11) 4 (80) *0.03 G 13 (72) 9 (50) 9 (90) 0.08
GA 5 (56) 7 (78) 1 (20) A 5 (28) 9 (50) 1 (10)
AA 0 0 1 (11) 0 0
rs2536512 GG 0 0 1 (11) 2 (40) 0.22 G 3 (17) 7 (39) 5 (50) 0.14
GA 3 (33) 5 (56) 1 (20) A 15 (83) 11 (61) 5 (50)
AA 6 (67) 3 (33) 2 (40)
rs1970951 TT 6 (67) 7 (78) 0 (0) *0.05 T 14 (78) 16 (89) 4 (40) *0.03
TC 2 (22) 2 (22) 4 (80) C 4 (22) 2 (11) 6 (60)
CC 1 (11) 0 (0) 1 (20)
rs381852 AA 4 (45) 5 (56) 1 (20) 0.32 A 12 (67) 13 (72) 4 (40) 0.25
AG 4 (45) 3 (33) 2 (40) G 6 (33) 5 (28) 6 (60)
GG 1 (10) 1 (11) 2 (40)
rs3763011 GG 1 (11) 2 (22) 0 (0) 0.91 G 8 (44) 9 (50) 4 (40) 0.93
GA 6 (67) 5 (56) 4 (80) A 10 (56) 9 (50) 6 (60)
AA 2 (22) 2 (22) 1 (20)
rs8177447 TT 7 (78) 8 (89) 3 (60) 0.55 T 15 (83) 17 (94) 7 (70) 0.25
TC 1 (11) 1 (11) 1 (20) C 3 (17) 1 (6) 3 (30)
CC 1 (11) 0 (0) 1 (20)
rs769217 CC 2 (22) 3 (34) 1 (20) 0.42 C 6 (33) 10 (56) 6 (60) 0.36
CT 2 (22) 4 (44) 4 (80) T 12 (67) 8 (44) 4 (40)
TT 5 (56) 2 (22) 0 (0)
rs769218 GG 2 (22) 3 (34) 0 (0) 0.54 G 6 (33) 10 (56) 4 (40) 0.48
GA 2 (22) 4 (44) 4 (80) A 12 (67) 8 (44) 6 (60)
AA 5 (56) 2 (22) 1 (20)
Note:
1 Genotype frequencies and 2allele frequencies were determined by Fisher’s exact test analysis and *p < 0.05 was considered statistically significant between the three
groups. All genotypes in MNG, PTC, and FTC populations were in associations with HW (p > 0.05).
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risk factors for thyroid disorders (Euge`ne, Djemli & Van Vliet, 2005; James & Kumar,
2012). The incidence of thyroid disorders was also reported to increase with age
(Sapini, Rokiah & Nor Zuraida, 2009). Our study also showed a higher proportion of
female patients compared to males.
Several studies have been conducted on the effects of thyroid hormones on antioxidant
status and oxidative stress (Babu, Jayaraaj & Prabhakar, 2011; Cano Europa, Margarita &
Rocio, 2012; Mancini et al., 2013). Although a majority of studies have reported increased
oxidative stress being positively correlated with thyroid disorders, some have also reported
the opposite or no changes (Venditti et al., 1997; Villanueva, Alva-Sanchez & Pacheco-
Rosado, 2013). Studies investigating antioxidant status in thyroid diseases may not include
all the crucial parameters to ascertain the relationship between thyroid diseases and
antioxidants. Most of the previous studies regarding antioxidant status in thyroid
diseases were performed either by evaluating antioxidants as a whole (Sivakanesan,
Wickramarathne & Nanayakkara, 2014; Wang et al., 2011), or by measuring each
antioxidants separately (Cetin et al., 2015; Erdamar et al., 2010; Senthil &Manoharan, 2004).
Figure 3 Venn diagrams of SNPs distribution among patients of MNG (M1–M9), PTC (P1–P9), and
FTC (F1–F5). Individual patients in each group; MNG (M1–M9), PTC (P1–P9), and FTC (F1–F5).
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Figure 4 Allelic frequencies distribution of the highlighted eight SNPs in SOD, GPX, and CAT genes
in our studied populations with comparison to the healthy individuals of South Asian (SAS) and
East Asian (EAS). The data of SAS and EAS populations were obtained from 1000 Genomes Project
Phase 3 allele frequencies (http://Ensembl.org).
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In order to overcome this limitation, in this study, we performed analyses to determine both
the antioxidant levels as well as parameters of oxidative stress in patients with thyroid
disorders to provide an overall picture with regards to the status of antioxidants and
oxidative damage.
We also compared these indicators between the benign and malignant forms of thyroid
disorders to ascertain their potential influence in the development of cancers from the
benign forms. Furthermore, we have also analysed the RBC to ascertain the effects of
the thyroid disorders on the antioxidant status of RBC. Previous reports have also
used thyroid tissues, however, due to difficulty in obtaining thyroid tissue samples,
comparisons were made between our results and other published results of thyroid tissues.
This will, at the same time, provide data on potential clinical application of serum in
thyroid disorders.
The 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) assay measures the
overall antioxidant capacity in the samples. The assay relies on the ability of antioxidants
in the serum sample to scavenge ABTS radicals and inhibit oxidation in comparison to
Trolox as the standard (Magalha˜es et al., 2008). Serum may contain some low molecular
weight compounds with antioxidant activities such as vitamin C, vitamin E, and uric
acid. Results from both serum and RBC samples in this study generally indicated
patients with thyroid diseases tend to have lower antioxidant activities in the serum but no
changes in RBC, compared to healthy subjects. A study by Wang et al. (2011) that
measured antioxidant status of thyroid cancer patients demonstrated similar results
as ours. Majority of studies have reported on the lowering of antioxidant activities
Figure 5 Associations between antioxidant enzyme activities and the total number of SNPs present
in MNG and PTC groups. (A) SNPs of SOD and SOD activities in MNG and PTC patients; (B) SNPs of
GPx and GPx activities in MNG and PTC patients: (C) SNPs of CATand CATactivities in MNG and PTC
patients. Data are presented as mean ± SEM. Spearman’s correlation coefficient test were expressed as r
for the total number of SNPs in each patients’ group, where applies.
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with hyperthyroidism (Andryskowski & Owczarek, 2007; Asayama et al., 1989; Venditti,
De Rosa & Di Meo, 2003) although one study has reported no significant changes
(Sivakanesan, Wickramarathne & Nanayakkara, 2014). The lower antioxidant activities
were accompanied with increased lipid peroxidation in serum of FTA group and increased
ROS in serum of PTC group, implying reduced ability to protect against oxidative stress in
these groups. Similar observation was seen for RBCs. PTC has the highest serum ROS
concentration among the studied group, possibly due to the substantial reduction in
serum antioxidant activities. When comparing the benign and malignant forms, there was
significant reduction in serum antioxidant activities which was accompanied with
increased ROS, in PTC group compared to MNG. The same could not be seen between
FTA and the malignant form, FTC. The malignancy of the thyroid gland could have led to
generation of high amounts of ROS, triggering oxidative stress which in turns lowers the
amount of antioxidants.
A study has reported increased MDA levels in thyroid tissues of PTC patients
compared to non-cancerous tissues (Erdamar et al., 2010). ROS consist of superoxide
anion (O2
-), hydroxyl radicals (OH-), nitric oxide (NO), and peroxyl radical (ROO-).
Their production may be influenced by antioxidant enzymes including SOD, CAT, and
GPx. SOD enzyme causes dismutation of superoxide anion radical, leading to production
of another radical, hydrogen peroxide (H2O2). CAT and GPx convert H2O2 into oxygen
and H2O (MatE´s, Pe´rez-Go´mez & De Castro, 1999).
In addition to endogenous antioxidants, the body protects against oxidative damage
through antioxidant enzymes. Studies have shown that oxidative stress can affect levels
of antioxidant enzymes (Gerenova & Gadjeva, 2005; Sivakanesan, Wickramarathne &
Nanayakkara, 2014; Villanueva, Alva-Sanchez & Pacheco-Rosado, 2013), hence measuring
their levels in this study can provide an indication of oxidative stress in the patients.
The increase in serum SOD and CAT activities in some of the thyroid disorder groups
indicated increased production of superoxide anion and hydrogen peroxide, respectively.
Superoxide anions are produced as by-products of the mitochondrial oxidation system.
As thyroid hormones also function to regulate the mitochondrial oxidation system,
disorders of the thyroid gland may have altered oxidation, leading to increased production
of superoxide anion. Similarly, reaction of SOD in removing superoxide anions leads
to the production of H2O2 and this explains the increased CAT activities. The increased
SOD and CAT activities could also be due to up-regulation in the synthesis of these
enzymes as a result of the thyroid disorders, as protective response against oxidative stress.
However, despite the increased SOD and CAT activities, MDA and ROS levels were still
elevated in some groups. This indicates the inability of the cells to completely scavenge
the radicals and implies that the rate of clearance of the ROS by these two enzymes is
slower than their production. Hyperthyroid rats were reported to have significantly
higher lipid peroxidation, SOD, CAT, and GPx in liver, together with lower serum
antioxidant status (Messarah et al., 2010). It was recently reported that changes in
lipid peroxidation and SOD between normal and PTC thyroid tissues can be used as
possible markers to differentiate between malignant and non-malignant thyroid tumours
(Stanley et al., 2016).
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Prolonged excessive production and inadequate removal of ROS can create an
oxidative stress environment, leading to DNA damage which can contribute to the
pathogenesis of the malignant state. It was recently reported that PRDX1 and PRDX6
expressions were significantly reduced in all PTCs compared to normal tissues, via
V600E mutation in the BRAF gene (Nicolussi et al., 2014). PRDXs play several roles in
the body including catalysing the reduction of H2O2. In a recent case report of a patient
with concurrent benign thyroid cyst and PTC, based on WES and mutation analyses,
it was hypothesised that prolonged H2O2 insult could interfere with the MAPK and
STAT3 pathways, causing malignant transformation of the benign thyroid nodule
(Lee et al., 2016).
Sadani & Nadkarni (1996) reported increasedMDA levels and SOD activities in thyroid
tissues of FTA, FTC, and PTC patients but no changes in the MNG group. Some of these
observations are similar to what we observed in serum of the patients, implying that
the changes seen in the serum could be the result of damage to the thyroid tissues. Also,
higher oxidative stress in the serum is indicative of tissue damage due to oxidation,
potentially damage from the thyroid tissues themselves. Indeed, studies have reported
reduced antioxidant activities and increased ROS production in thyroid glands of patients
with thyroid disorders (Sarkar et al., 2006; Venditti, De Rosa & Di Meo, 2003; Villanueva,
Alva-Sanchez & Pacheco-Rosado, 2013).
Results for antioxidant activities, lipid peroxidation and ROS levels obtained in the
RBC were similar to serum, in some instances, while for others, were different. SOD
activity of RBC was lower than control. One interesting observation from the results
of the RBC is the substantial reduction of GPx activities in both malignant forms of
the thyroid disorder, PTC and FTC. Asayama et al. (1989) and Ferna´ndez & Videla
(1989) have reported significant reduction in GPx activity of rats suffering from
hyperthyroidism.
A study reported increased antioxidant enzyme activities in erythrocytes of toxic MNG
patients, which is the opposite of what we observed in RBC (Alicigu¨zel et al., 2001).
Another study also reported increased GPx in both hyper- and hypo-thyroid rats but
no changes in SOD and CAT (Araujo et al., 2011). It has been reported that erythrocytes
of patients/animals with hyperthyroidism showed increased oxygen consumption
(Alicigu¨zel et al., 2001), while Sarkar et al. (2006) also reported the same observation in
peripheral blood mononuclear cells (PMC). This may potentially lead to increased
production of ROS, hence altering the redox balance of erythrocytes, in favour of
oxidative stress.
Results from our study seem to indicate higher oxidative stress in the serum as opposed
to RBC. We speculated that RBC may contain antioxidant response system that is
better able to counter the effects of increased ROS production as a result of thyroid
disorders. Erythrocytes are exposed to endogenous and exogenous sources of ROS
including superoxide anion and H2O2. However, they are equipped with antioxidant
system comprising of non-enzymatic and enzymatic antioxidants, the latter includes CAT,
SOD, and GPx. The especially low levels of GPx in PTC and FTC groups indicated
the inability of erythrocytes to scavenge H2O2, which is depicted by the increase in
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ROS and MDA levels. The reduction seen in both the malignant forms implies the
possibility of the tumour affecting GPx activities or vice versa. Deficiency of GPx has
been associated with several conditions. Cells/tissues deficient in GPx are more susceptible
to oxidative damage, apoptosis, cell injury, and cell death (Flentjar et al., 2002;
Van Remmen et al., 2004). The substantial reduction in GPx activities in the malignant
form of thyroid disorders can be further explored with the aim of potentially using
this enzyme as a biomarker.
As antioxidant enzymes evolve to maintain cellular redox homeostasis, their enzymatic
activities may be influenced either directly or indirectly by the respective genes that encode
them (Gelain et al., 2009). SOD enzyme is encoded by three different isoforms; SOD1,
SOD2, and SOD3. Both SOD1 and SOD3 contain copper and zinc in their catalytic
centre but are localised differently; SOD1 is present in the cytosol (CuZn-SOD), while
SOD3 is found in the extracellular elements (EC-SOD). SOD2 has manganese as a cofactor
and is localised in the mitochondria (Mn-SOD) (Zelko, Mariani & Folz, 2002). GPx
enzyme is encoded by eight different isoforms (GPX1–GPX8) which are localised mostly
in the cytosol, nucleus, and extracellular space. CAT enzyme, encoded by CAT gene, is
localised in peroxisomes (Margis et al., 2008). Whole exome sequencing analysis resulted
in identification of SNPs present in the antioxidant enzyme genes of all 18 patients
(MNG and PTC).
Whole exome sequencing analysis resulted in identification of SNPs present in the
antioxidant enzyme genes of all 18 patients (MNG and PTC). rs752779 was the most
common SNP detected in the patients in this study. This SNP is located at the intergenic
region of SOD2 and WTAP genes of chromosome 6q25.3. To date, there is no reported
study on the association of this SNP with disease development. rs2536512 is the SNP
of SOD3 gene that is located on chromosome 4p15.2. It is a missense variant identified
in exon 2 of SOD3 with the base change of G to A, and amino acid substitution of
Alanine to Threonine (A58T). This SNP was reported to be associated with type 2 diabetes
and hypertension (Naganuma et al., 2008). A previous study has also reported the
association of rs2536512 SNP with significantly greater incidence of breast carcinoma
(Hubackova et al., 2012). Although the rs2536512 SNP is non-functional, it was
hypothesised that this SNPmay act as a genetic marker for susceptibility to type 2 diabetes
and hypertension (Naganuma et al., 2008; Tamai et al., 2006).
The rs1970951 SNP is a synonymous variant identified in exon 2 of GPX7 gene with a
base change of T to C,maintaining the amino acid phenylalanine (F79F). There is no known
link between this SNP with any diseases. rs381852 is a missense variant identified in exon 3
of GPX8 gene with the base change of A to G, and amino acid substitution of Lysine to
Arginine (K182R). Meanwhile, both rs3763011 and rs8177447 are from GPX3 gene located
at intron 1 and intron 4, respectively. CAT is the only enzyme without isoforms, and is
encoded by the CAT gene. rs769217 is a synonymous variant in exon 9 of CAT gene with
base change of C to Twithout the substitution of Aspartic acid, while C6 rs769218 is located
at intron 1. There is also no known link between this SNP with any diseases.
A Spearman’s correlation coefficient was performed to investigate if an association
exists between the antioxidant enzyme activities and SNPs in the genes encoding the
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antioxidant enzymes, in the thyroid disorder patients. Based on results of the SOD
enzyme, the malignant group has a lower number of SNPs (n = 49) compared to the
benign group (n = 55) (Fig. 5A). However, for GPX and CAT (Figs. 5B and 5C),
both showed a higher number of SNPs for the malignant groups compared to the
benign groups. Nevertheless, there was no significant correlation observed. This
indicates that the SNPs for SOD, GPx, and CAT do not appear to influence the
corresponding enzyme activities. Interestingly, although not significant, there appeared
to be a trend of negative association between SNPs of CAT and GPX with the respective
antioxidant enzyme activities, for the benign group whilst a positive association was
observed for the malignant group. Further studies using larger sample size could validate
this observation. A particular SNP may indicate that one form of the gene is common
in some people with that particular trait, which means that the incidence of having
certain allele frequency may be linked with the history of the trait rather than affecting
the body system mechanisms.
CONCLUSION
This study demonstrates that patients with thyroid disorders have lower antioxidant
defence system, potentially predisposing them to oxidative stress. Additionally, different
forms of thyroid disorders could influence the levels of antioxidant status in the serum
and RBC of these patients, implying varying capability of preventing oxidative stress.
No significant association was observed between serum enzyme activities and the
total number of SNPs identified in this study. SNP-disease association study however,
demonstrated that the genotypic (and allelic) distributions of rs752779 and rs1970951
are markedly different among subjects with malignant thyroid disorders. The lack of
association between other SNPs and thyroid disorders need to be validated in a larger
sample size using appropriate controls subjects.
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